Steven Pieper - 28 Jul 2021 Form 3 Insider Report for XERIS PHARMACEUTICALS INC

Role
Senior Vice President, General Counsel and Corporate Secretary Exhibit 24.1: Power of Attorney attached
Signature
/s/ Beth Hecht
Issuer symbol
N/A
Transactions as of
28 Jul 2021
Net transactions value
$0
Form type
3
Filing time
29 Jul 2021, 18:04:31 UTC
Next filing
05 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XERS Common Stock 58,858 28 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XERS Stock Option (Right to Buy) 28 Jul 2021 Common Shares 16,843 $1.55 Direct F1, F2
holding XERS Stock Option (Right to Buy) 28 Jul 2021 Common Shares 2,640 $1.55 Direct F1, F2
holding XERS Stock Option (Right to Buy) 28 Jul 2021 Common Shares 14,036 $5.93 Direct F1, F2
holding XERS Stock Option (Right to Buy) 28 Jul 2021 Common Shares 6,532 $6.37 Direct F1
holding XERS Stock Option (Right to Buy) 28 Jul 2021 Common Shares 5,968 $6.37 Direct F1
holding XERS Stock Option (Right to Buy) 28 Jul 2021 Common Shares 27,891 $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months
F2 These options are early exercisable.

Remarks:

Senior Vice President, General Counsel and Corporate Secretary Exhibit 24.1: Power of Attorney attached